Diagnostic and Pathologic Value of Programmed Death-Ligand 1 Expression in Colon Carcinoma

Objectives: To evaluate the diagnostic value of programmed death-ligand1 expression in colon carcinoma cells and its correlation with different pathological features. Methods: An immunohistochemical study was conducted on 50 cases diagnosed as colon carcinoma over a one year period from October 201...

Full description

Bibliographic Details
Main Authors: Dina Omar Helmy, Mahmoud Tag El-Sabah, Mohamed Sherif Negm, Mina Ezzat Onsy Armia
Format: Article
Language:English
Published: West Asia Organization for Cancer Prevention 2020-12-01
Series:Asian Pacific Journal of Cancer Biology
Subjects:
Online Access:http://www.waocp.com/journal/index.php/apjcb/article/view/585
_version_ 1797341129040986112
author Dina Omar Helmy
Mahmoud Tag El-Sabah
Mohamed Sherif Negm
Mina Ezzat Onsy Armia
author_facet Dina Omar Helmy
Mahmoud Tag El-Sabah
Mohamed Sherif Negm
Mina Ezzat Onsy Armia
author_sort Dina Omar Helmy
collection DOAJ
description Objectives: To evaluate the diagnostic value of programmed death-ligand1 expression in colon carcinoma cells and its correlation with different pathological features. Methods: An immunohistochemical study was conducted on 50 cases diagnosed as colon carcinoma over a one year period from October 2018 to October 2019.The paraffin blocks were received from the Pathology Departments, Faculty of Medicine, Cairo University and Misr University for Science and Technology (MUST). The diagnosis of colon carcinoma for all cases was revised using H&E stain. The immunohistochemical expression of programmed death- ligand1 was assessed using immune reactive score method. The personal data, clinical details and pathological diagnosis were recorded and correlated with programmed death-ligand1 expression. Results: This study included 50 cases of colon carcinoma. There was a male predominance with female to male ratio 1:1.08.The age of patients was ranged from 30 years to 76 years with mean age 53.3± 11.2 years. The majority of cases (44%) were invasive adenocarcinoma followed by invasive adenocarcinoma with mucoid activity (18%), invasive adenocarcinoma with neuroendocrine differentiation (16%), invasive signet ring carcinoma (14%) and invasive mucinous carcinoma (8%). Immune reactive score for programmed death-ligand1 had a Mean ± Standard Deviation of 8.4 ± 4.2. Strong immune reactive score was represented by 58% of cases, moderate immune reactive score was represented by 24% of cases and only one case (2%) had mild immune reactive score. The remaining 16% of cases were negative. Correlation between immune reactive score of programmed death-ligand1and tumor type, size and lymph-vascular invasion was statistically significant. Cases with marked immune reactive score for programmed death-ligand1 showed highest predilection for invasive adenocarcinoma with neuroendocrine differentiation, large sized tumors and lymph-vascular invasion. Conclusion: The expression of programmed death-ligand1 using immune reactive score method can estimate the growth of colon carcinoma, invasive adenocarcinoma with neuroendocrine differentiation and lymph-vascular spread. Further large scale studies utilizing programmed death-ligand 1can aid in identifying the prognosis and therapeutic possibilities for patients with colon cancer.
first_indexed 2024-03-08T10:14:07Z
format Article
id doaj.art-e4fcd235e0b64646ab8475d138307772
institution Directory Open Access Journal
issn 2538-4635
language English
last_indexed 2024-03-08T10:14:07Z
publishDate 2020-12-01
publisher West Asia Organization for Cancer Prevention
record_format Article
series Asian Pacific Journal of Cancer Biology
spelling doaj.art-e4fcd235e0b64646ab8475d1383077722024-01-29T06:17:25ZengWest Asia Organization for Cancer PreventionAsian Pacific Journal of Cancer Biology2538-46352020-12-015415916610.31557/apjcb.2020.5.4.159-166585Diagnostic and Pathologic Value of Programmed Death-Ligand 1 Expression in Colon CarcinomaDina Omar Helmy0Mahmoud Tag El-Sabah1Mohamed Sherif Negm2Mina Ezzat Onsy Armia3Pathology Department, College of Medicine, Cairo University, Cairo, EgyptPathology Department, College of Medicine, MUST University, 6th October City, Giza, Egypt.Pathology Department, College of Medicine, Cairo University, Cairo, Egypt.Pathology Department, College of Medicine, MUST University, 6th October City, Giza, Egypt.Objectives: To evaluate the diagnostic value of programmed death-ligand1 expression in colon carcinoma cells and its correlation with different pathological features. Methods: An immunohistochemical study was conducted on 50 cases diagnosed as colon carcinoma over a one year period from October 2018 to October 2019.The paraffin blocks were received from the Pathology Departments, Faculty of Medicine, Cairo University and Misr University for Science and Technology (MUST). The diagnosis of colon carcinoma for all cases was revised using H&E stain. The immunohistochemical expression of programmed death- ligand1 was assessed using immune reactive score method. The personal data, clinical details and pathological diagnosis were recorded and correlated with programmed death-ligand1 expression. Results: This study included 50 cases of colon carcinoma. There was a male predominance with female to male ratio 1:1.08.The age of patients was ranged from 30 years to 76 years with mean age 53.3± 11.2 years. The majority of cases (44%) were invasive adenocarcinoma followed by invasive adenocarcinoma with mucoid activity (18%), invasive adenocarcinoma with neuroendocrine differentiation (16%), invasive signet ring carcinoma (14%) and invasive mucinous carcinoma (8%). Immune reactive score for programmed death-ligand1 had a Mean ± Standard Deviation of 8.4 ± 4.2. Strong immune reactive score was represented by 58% of cases, moderate immune reactive score was represented by 24% of cases and only one case (2%) had mild immune reactive score. The remaining 16% of cases were negative. Correlation between immune reactive score of programmed death-ligand1and tumor type, size and lymph-vascular invasion was statistically significant. Cases with marked immune reactive score for programmed death-ligand1 showed highest predilection for invasive adenocarcinoma with neuroendocrine differentiation, large sized tumors and lymph-vascular invasion. Conclusion: The expression of programmed death-ligand1 using immune reactive score method can estimate the growth of colon carcinoma, invasive adenocarcinoma with neuroendocrine differentiation and lymph-vascular spread. Further large scale studies utilizing programmed death-ligand 1can aid in identifying the prognosis and therapeutic possibilities for patients with colon cancer.http://www.waocp.com/journal/index.php/apjcb/article/view/585pdl1- colon carcinoma- ihc
spellingShingle Dina Omar Helmy
Mahmoud Tag El-Sabah
Mohamed Sherif Negm
Mina Ezzat Onsy Armia
Diagnostic and Pathologic Value of Programmed Death-Ligand 1 Expression in Colon Carcinoma
Asian Pacific Journal of Cancer Biology
pdl1- colon carcinoma- ihc
title Diagnostic and Pathologic Value of Programmed Death-Ligand 1 Expression in Colon Carcinoma
title_full Diagnostic and Pathologic Value of Programmed Death-Ligand 1 Expression in Colon Carcinoma
title_fullStr Diagnostic and Pathologic Value of Programmed Death-Ligand 1 Expression in Colon Carcinoma
title_full_unstemmed Diagnostic and Pathologic Value of Programmed Death-Ligand 1 Expression in Colon Carcinoma
title_short Diagnostic and Pathologic Value of Programmed Death-Ligand 1 Expression in Colon Carcinoma
title_sort diagnostic and pathologic value of programmed death ligand 1 expression in colon carcinoma
topic pdl1- colon carcinoma- ihc
url http://www.waocp.com/journal/index.php/apjcb/article/view/585
work_keys_str_mv AT dinaomarhelmy diagnosticandpathologicvalueofprogrammeddeathligand1expressionincoloncarcinoma
AT mahmoudtagelsabah diagnosticandpathologicvalueofprogrammeddeathligand1expressionincoloncarcinoma
AT mohamedsherifnegm diagnosticandpathologicvalueofprogrammeddeathligand1expressionincoloncarcinoma
AT minaezzatonsyarmia diagnosticandpathologicvalueofprogrammeddeathligand1expressionincoloncarcinoma